PATENT COOPERATION TREATY

REC'D 12 MAY 2005

PCT

WIPO PCT

INTERNATIONAL PRELIMINARY REPORT ON PATENTABILITY (Chapter II of the Patent Cooperation Treaty)

(PCT Article 36 and Rule 70)

Applicant's or agent's file reference 028750-236		FOR FURTHER ACTION	See Form PCT/IPEA/416					
International application No.		International filing date (day/month/year)	Priority date (day/month/year)					
PCT/US04/08399		19 March 2004 (19.03.2004)	19 March 2003 (19.03.2003)					
International Pate	ent Classification (IPC)	or national classification and IPC						
	16 and US Cl.: 424/490							
Applicant		-						
UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION								
1. This report is the international preliminary examination report, established by this International Preliminary Examining Authority under Article 35 and transmitted to the applicant according to Article 36.								
2. This								
a. [] (sent to the applica	nt and to the International Bureau) a total o	f sheets, as follows:					
sheets of the description, claims and/or drawings which have been amended and are the basis of this report and/or sheets containing rectifications authorized by this Authority (see Rule 70.16 and Section 607 of the Administrative Instructions).								
	sheets which supersede earlier sheets, but which this Authority considers contain an amendment							
	that goes bey	and the disclosure in the international appli	cation as filed, as indicated in item 4 of					
ъ. Г		I the Supplemental Box.						
, <u>.</u>	containing .	tional Bureau only) a total of (indicate type a	and number of electronic carrier(s))					
, containing a sequence listing and/or tables related thereto, in computer readable form only, as indicated in the Supplemental Box Relating to Sequence Listing (see Section 802 of the Administrative Instructions).								
4. This report contains indications relating to the following items:								
\boxtimes								
. 🗆	Box No. II Pri	ority						
	Box No. III No	n-establishment of opinion with regard to n	ovelty, inventive step and industrial					
	ap	olicability						
	Box No. IV La	ck of unity of invention	,					
	Box No. V Re	Reasoned statement under Article 35(2) with regard to novelty, inventive step or						
		industrial applicability, citations and explanations supporting such statement Certain documents cited						
		Certain defects in the international application						
\boxtimes		rtain observations on the international applic	ration					
Date of submission of the demand Date of completion of this report								
Sate of completion of this report								
19 January 2005 (19.01.2005) Name and mailing address of the IPEA/ US Authorized a Grand Company 1 of the IPEA/ US								
Mail Stop PCT, Attn: PRA/US								
Commissioner for Patents P.O. Box 1450 BLESSING FUBARA								
Alexandria, Virginia 22313-1450								
Facsimile No. (703) 305-3230 Telephone No. 571-272-1600 Corm PCT/IPEA/409 (cover sheet)(January 2004)								

INTERNATIONAL PRELIMINARY REPORT ON PATENTABILITY

International application No.	
PCT/US04/08399	

Box No. I Basis of the report
1. With regard to the language, this report is based on the international application in the language in which it was filed unless otherwise indicated under this item.
This report is based on translations from the original language into the following language, which is the language of a translation furnished for the purposes of:
international search (under Rules 12.3 and 23.1(b))
publication of the international application (under Rule 12.4)
international preliminary examination (under Rules 55.2 and/or 55.3)
2. With regard to the elements of the international application, this report is based on (replacement sheets which have been furnished annexed to this report): annexed to this report):
the international application as originally filed/furnished
the description:
pages 1-41 as originally filed/furnished
pages* NONE received by this Authority on
received by this Authority on
var varing.
pages 42-45 as originally filed/furnished pages* NONE as amended (together with any statement) under Article 10
pages* NONE received by this Authority on
pages* NONE received by this Authority on
the drawings:
pages 1-8 as originally filed/formished
pages* NONE received by this Authority on
pages* NONE received by this Authority on
a sequence listing and/or any related table(s) - see Supplemental Box Relating to Sequence Listing.
3. The amendments have resulted in the cancellation of:
the description, pages
the claims, Nos
the drawings, sheets/figs
the sequence listing (specify):
any table(s) related to the sequence listing (specify):
4. This report has been established as if (some of) the amendments annexed to this report and listed below had not been made, since they have been considered to go beyond the disclosure as filed, as indicated in the Supplemental Box (Rule 70.2(c)).
the description, pages
the claims, 190s
the drawings, sheets/figs
the sequence listing (specify):
any table(s) related to the sequence listing (specify):
* If item 4 applies, some or all of those sheets may be marked "superseded,"
rm PCT/IPEA/409 (Box No. I) (January 2004)

INTERNATIONAL PRELIMINARY REPORT ON PATENTABILITY

International application No. PCT/US04/08399

Box No. V Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement						
1. Statement						
Novelty (N)	Claims 1-15 Claims NONE	YES				
Inventive Step (IS)	Claims 1-15 Claims NONE	YES NO				
Industrial Applicability (IA)	Claims <u>1-15</u> Claims <u>NONE</u>	YES				

2. Citations and Explanations (Rule 70.7)

Claims 1-15 meet the criteria set out in PCT Article 33(2)-(3), because the prior art does not teach or fairly suggest a microsphere composition comprises a composite of PLGA, polyacryloyl hydroxyethyl starch and a biologically active compound.

Claims 1-15 meet the criteria set out in PCT Article 33(4), and thus have industrial applicability in the polymer drug delivery art and the subject matter claimed can be made or used in industry.

Deluca et al. (US 5,160,745) discloses biodegradable three dimensional microspheres and biologically active macromolecular agents are entrapped within the polymer network (abstract). Preferred biologically active macromolecular agents are peptides and proteins (column 3, lines 53-68; column 7, lines 3-16). The biodegradable 3-d polymers are hydrophilic and can include derivatives of polysaccharides such as hydrolyzed amylopectin; an example of which is hydroxyethyl starch (HES) (column 5, lines 6-10). The 3-d hydrophilic net work is obtained by free radical polymerization of two vinyl or substituted vinyl groups such as acryloyl (column 5, lines 38-63) with additional monovinylic monomer such as N-acryloyl-N'-dimethylamino propylamine (column 6, lines 57-68). Similarly, acryloyl chloride can react with hydroxyl or amino groups of the biodegradable hydrophilic polymer (column 6, lines 2-7). The system of Deluca does not have PLGA to form a composite with the hydroxyethyl starch (HES).

Berde et al. (US 5,922,340) discloses a sustained release microsphere composition that comprises controlled release biocompatible carriers selected from the group consisting of PLGA, polyorthoesters, polycaprolactones, soluble derivatives of polysaccharides such as HES (column 8, lines 37-65) and biologically active agent (claim 7).

There is no teaching in the references to form composite of the PLGA and the hydroxyethyl starch (HES) that has been derivatized with

Form PCT/IPEA/409 (Box No. V) (January 2004)

INTERNATIONAL PRELIMINARY REPORT ON PATENTABILITY

International application No.

PCT/US04/08399

Box No.	VIII	Certain observations on	the international	application
---------	------	-------------------------	-------------------	-------------

The following observations on the clarity of the claims, description, and drawings or on the question whether the claims are fully supported by the description, are made:

Claim 7 is objected to under PCT Rule 66.2(a)(v) as lacking clarity under PCT Article 6 because claim is indefinite for the following reason(s): Claim 7 depends from claim 4 and claim 4 or the claim from which it depends from does not recite a primate and claim 7 does not have antecedence for primate.

Form PCT/IPEA/409 (Box No. VIII) (January 2004)